JP2011012060A5 - - Google Patents

Download PDF

Info

Publication number
JP2011012060A5
JP2011012060A5 JP2010147994A JP2010147994A JP2011012060A5 JP 2011012060 A5 JP2011012060 A5 JP 2011012060A5 JP 2010147994 A JP2010147994 A JP 2010147994A JP 2010147994 A JP2010147994 A JP 2010147994A JP 2011012060 A5 JP2011012060 A5 JP 2011012060A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antitrypsin
alpha
treatment
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010147994A
Other languages
English (en)
Japanese (ja)
Other versions
JP5231490B2 (ja
JP2011012060A (ja
Filing date
Publication date
Priority claimed from ES200930387A external-priority patent/ES2332645B1/es
Application filed filed Critical
Publication of JP2011012060A publication Critical patent/JP2011012060A/ja
Publication of JP2011012060A5 publication Critical patent/JP2011012060A5/ja
Application granted granted Critical
Publication of JP5231490B2 publication Critical patent/JP5231490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010147994A 2009-06-30 2010-06-29 慢性疲労症候群の治療用の医薬の製造のための、アルファ−1−アンチトリプシンの使用 Active JP5231490B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930387 2009-06-30
ES200930387A ES2332645B1 (es) 2009-06-30 2009-06-30 Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.

Publications (3)

Publication Number Publication Date
JP2011012060A JP2011012060A (ja) 2011-01-20
JP2011012060A5 true JP2011012060A5 (https=) 2011-03-31
JP5231490B2 JP5231490B2 (ja) 2013-07-10

Family

ID=41571181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010147994A Active JP5231490B2 (ja) 2009-06-30 2010-06-29 慢性疲労症候群の治療用の医薬の製造のための、アルファ−1−アンチトリプシンの使用

Country Status (16)

Country Link
US (1) US9205134B2 (https=)
EP (1) EP2289540B1 (https=)
JP (1) JP5231490B2 (https=)
CN (1) CN101934071B (https=)
AR (1) AR077123A1 (https=)
AU (1) AU2010202203B2 (https=)
BR (1) BRPI1002087B1 (https=)
CA (1) CA2706212C (https=)
CL (1) CL2010000575A1 (https=)
ES (2) ES2332645B1 (https=)
MX (1) MX2010006125A (https=)
NZ (1) NZ585890A (https=)
PL (1) PL2289540T3 (https=)
PT (1) PT2289540E (https=)
RU (1) RU2436590C1 (https=)
UY (1) UY32670A (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2793936A4 (en) * 2011-12-19 2015-05-27 Lfb Usa Inc RECOMBINANT HUMAN ALPHA-1-ANTITRYPINE FOR THE TREATMENT OF INFLAMMATORY DISEASES
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281222A (en) * 1941-09-27 1942-04-28 American Bosch Corp Speed regulator for internal combustion engines
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
WO1992020327A1 (en) * 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
CN1450898A (zh) * 2000-04-21 2003-10-22 法玛西雅厄普约翰美国公司 用于治疗纤维肌痛和慢性疲劳综合症的化合物
US20040043510A1 (en) * 2000-07-14 2004-03-04 Nobuyuki Shigetoh Particle-labeled protein and immuno-chromatograph using the same
CA2506839A1 (en) 2002-11-20 2004-06-03 Prometic Biosciences, Inc. Composition and method for treating inflammatory diseases using protease inhibitors
US7344882B2 (en) 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
US7850970B2 (en) * 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2006026837A1 (en) * 2004-09-07 2006-03-16 Patrick Englebienne Diagnostic methods for measuring elastase activity levels
ES2281222B1 (es) * 2004-09-24 2008-06-01 Grifols, S.A. Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
WO2008143633A2 (en) * 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
WO2009042193A1 (en) * 2007-09-25 2009-04-02 Abbott Laboratories Octahydropentalene compounds as chemokine receptor antagonists
PL2214699T3 (pl) 2007-11-02 2017-05-31 Grifols Therapeutics Inc. Sposób, kompozycja i wyrób do dostarczania alfa1-antytrypsyny

Similar Documents

Publication Publication Date Title
JP2013520405A5 (https=)
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
EP2749280A3 (en) Combination of glycopyrronium and formoterol
JP2015517983A5 (https=)
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
JP2012092110A5 (https=)
MY159058A (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
JP2015517488A5 (https=)
LT3133070T (lt) Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2014503593A5 (https=)
CO6612185A2 (es) Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos
PE20150171A1 (es) Nueva forma de dosificacion y formulacion de abediterol
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
JP2013533269A5 (https=)
WO2013058484A3 (ko) 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
JP2014532722A5 (https=)
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
JP2011012060A5 (https=)